Sugi Predict

Sugi Predict / Compounds / SCHEMBL1990159

SCHEMBL1990159

SCHEMBL1990159

CC(C)(C)OC(=O)N1CCCN(c2ccc(N)nc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.53
▸ SKP1 P63208 2/20 0.53
▸ SKP2 Q13309 2/20 0.53
▸ GPR119 Q8TDV5 5/20 0.53
▸ MAPT P10636 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ TSHR P16473 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ATR Q13535 1/20 0.49
▸ PIK3CA P42336 1/20 0.48
▸ MAP4K4 O95819 1/20 0.47
▸ WNT3A P56704 1/20 0.46
▸ TRPC6 Q9Y210 2/20 0.46
▸ PTPN11 Q06124 1/20 0.46
▸ PDK2 Q15119 1/20 0.46
▸ NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30316131 1.00 CKS1B (0.53) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL1393764 0.95 MAPT (0.56) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL29426702 0.95 MAPT (0.56) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL29437363 0.94 GPR119 (0.55) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL26641577 0.94 MAPT (0.58) CKS1BSKP1SKP2GPR119MAPT
Ammonia Solution, Strong SCHEMBL28415331 0.94 GPR119 (0.55) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL30643550 0.88 GPR119 (0.52) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL26641386 0.88 GPR119 (0.52) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL6352769 0.86 CKS1B (0.59) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL6358835 0.86 CKS1B (0.53) CKS1BSKP1SKP2GPR119MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2026-05-28 — — US disclosed
CN-118871445-A Fused triazinone derivatives and methods of use thereof 亚根达医疗公司 2024-10-29 — — CN disclosed
CN-111333627-B Substituted 2-hydro-pyrazole derivatives as anticancer agents 正大天晴药业集团股份有限公司 2024-09-13 — — CN disclosed
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LTD. (GB) 2024-02-08 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
WO-2023086959-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-05-19 — — WO disclosed
US-20230096641-A1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-30 — — US disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
US-8415355-B2 Pyrrolopyrimidine compounds and their uses NOVARTIS AG (CH) 2013-04-09 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
EP-2331547-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS Novartis AG (CH) 2011-06-15 — — EP disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK9, CDK6, CDK7 CKS1B 38/4885SKP1 468/4885SKP2 153/4885
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CKS1B 49/4885SKP1 204/4885SKP2 59/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 CKS1B 663/4885SKP1 873/4885SKP2 727/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 CKS1B 58/4885SKP1 197/4885SKP2 63/4885
US-20230096641-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 CKS1B 663/4885SKP1 873/4885SKP2 727/4885
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CKS1B 49/4885SKP1 204/4885SKP2 59/4885
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 CKS1B 49/4885SKP1 204/4885SKP2 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.